BACKGROUND: The ability to reduce the administration frequency of subcutaneous (SC) @entity1307 could provide benefits. This multicenter open-label study investigated the therapeutic equivalence of SC @entity1307 beta once-weekly and thrice-weekly administration regimens in maintaining @entity417 correction in stable hemodialysis (HD) @entity1 . METHODS: One hundred seventy-three @entity1 were randomly assigned to either once-weekly @entity1307 beta (n = 84) or their original thrice-weekly regimen (n = 89) for 24 weeks. All @entity1 were administered intravenous @entity68 supplementation, as required. RESULTS: The per-protocol analysis included 134 @entity1 (69 @entity1 , once-weekly group; 65 @entity1 , thrice-weekly group). Mean hematocrits in both groups remained stable throughout the study. The difference in mean time-adjusted area under the curve for hematocrits between the once-weekly and thrice-weekly groups (-0.54 vol%) and 90% confidence intervals (-1.27 to 0.19) were within the prespecified equivalence range (-2 to +2 vol%). There was no significant change in @entity1307 beta dose during the study. The ratio of mean weekly @entity1307 beta doses in the once-weekly and thrice-weekly groups (1.11) and 90% confidence interval (0.99 to 1.23) also remained within the prespecified range (0.8 to 1.25). Intention-to-treat analysis results were similar to per-protocol analysis results. Both regimens were well tolerated. CONCLUSION: Once-weekly and thrice-weekly SC @entity1307 beta administrations are statistically equivalent in terms of maintaining both stable hematocrits and @entity1307 beta dose requirements in HD @entity1 . These findings may improve compliance among @entity1 .

Once-weekly compared with three-times-weekly subcutaneous XXXX beta: results from a randomized, multicenter, therapeutic-equivalence study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity1307 :: ('2056', 'Gene') :: ['epoetin'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['iron']
@entity1307 :: (2056,Gene) :: ['epoetin']
